Skip to main content

Table 2 Laboratory results at various time points

From: Incidence of anti-platelet factor4/polyanionic antibodies, thrombocytopenia, and thrombosis after COVID-19 vaccination with ChAdOx1 nCoV-19 in Thais

Characteristics

Type of vaccine

First dose ChAdOx1

(nā€‰=ā€‰305)*

Second dose ChAdOx1

(nā€‰=ā€‰265)**

CoronaVac/CoronaVac/ChAdOx1 (nā€‰=ā€‰364)***

Ā 

Day 0

(nā€‰=ā€‰304)

Day 10

(nā€‰=ā€‰278)

Day 28

(nā€‰=ā€‰275)

Day 0

(nā€‰=ā€‰264)

Day 10

(nā€‰=ā€‰240)

Day 28

(nā€‰=ā€‰249)

Day 0

(nā€‰=ā€‰364)

Day 10

(nā€‰=ā€‰333)

Day 28

(nā€‰=ā€‰336)

PF4/polyanion EIA +, n (%)

5 (1.6)

4 (1.4)

4 (1.5)

7 (2.7)

7 (2.9)

7 (2.8)

6 (1.7)

6 (1.8)

5 (1.5)

D-dimer, ng/L FEU (median, IQR)

270

(165ā€“410)

308

(200ā€“510)

270

(160ā€“440)

235

(140ā€“380)

230

(140ā€“380)

210

(140ā€“350)

245

(170ā€“370)

260

(180ā€“380)

240

(160ā€“370)

Platelet count, x 109/L (mean, SD)

272

(64.3)

273

(65.9)

272

(66.4)

264

(63.0)

282

(63.7)

275

(64.5)

301

(64.5)

324

(70.0)

298

(66.7)

  1. * 91 participants received only first dose of ChAdOx1 and 214 participants received both first and second dose of ChAdOx1.
  2. ** 214 participants received both first and second dose of ChAdOx1 and 51 participants received only second dose of ChAdOx1.
  3. *** Since these participants had first exposure to ChAdOx1, they were included in the study